- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT04973163
Um estudo para testar diferentes doses de BI 1823911 sozinho e combinado com outros medicamentos em pessoas com diferentes tipos de câncer avançado com mutação KRAS
Um estudo de fase Ia/Ib, open-label, multicêntrico de escalonamento de dose e expansão para investigar a segurança, a farmacocinética e a eficácia preliminar do BI 1823911 como monoterapia e em combinação com outras terapias anticancerígenas em pacientes com expressão de tumores sólidos avançados ou metastáticos Mutação KRAS G12C
This study is open to adults with different types of advanced or metastatic cancer (including lung cancer, colorectal cancer, pancreatic cancer, and bile duct cancer). This study is for people for whom previous treatment was not successful or no treatment exists.
People who have a tumour with a KRAS mutation can participate in the study. A KRAS mutation makes tumours grow faster. BI 1823911 and BI 1701963 are medicines that may turn off KRAS, each in a different way. In this study, BI 1823911 is given to people for the first time.
The purpose of this study is to find the highest dose of BI 1823911 that people can tolerate when taken alone and together with BI 1701963. The most suitable dose is used to find out whether BI 1823911 alone and in combination with BI 1701963 can make tumours shrink.
Participants can stay in the study as long as they benefit from treatment and can tolerate it.
During this time, participants take tablets of BI 1823911 alone or in combination with BI 1701963 once a day. The doctors regularly monitor the size of the tumour. Doctors also regularly record any unwanted effects and check participant's health.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 1
Contactos e Locais
Locais de estudo
-
-
-
Anderlecht/Brussels-Capital, Bélgica, 1070
- Brussels - HOSP Jules Bordet
-
Edegem/Antwerpen, Bélgica, 2650
- Universitair Ziekenhuis Antwerpen
-
Gent/Oost-Vlaanderen, Bélgica, 9000
- Universitair Ziekenhuis Gent
-
Leuven/Vlaams-Brabant, Bélgica, 3000
- UZ Leuven
-
-
-
-
-
Barcelona, Espanha, 08035
- Hospital Universitari Vall d'Hebron
-
-
-
-
New York
-
New York, New York, Estados Unidos, 10021
- Memorial Sloan-Kettering Cancer Center
-
-
Texas
-
Dallas, Texas, Estados Unidos, 75230
- Sarah Cannon Research Institute at Mary Crowley
-
Houston, Texas, Estados Unidos, 77030
- The University of Texas MD Anderson Cancer Center
-
-
-
-
-
Manchester, Reino Unido, M20 4BX
- The Christie
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
-
Pathologically confirmed diagnosis of locally advanced or metastatic solid tumours, e.g. adenocarcinoma of the lung, colorectal cancer, pancreatic cancer or cholangiocarcinoma. Non-small cell lung cancer (NSCLC) patients with mixed histology are eligible if adenocarcinoma is the predominant histology.
-
Documented disease progression despite appropriate prior standard therapies or for whom no standard therapy exists for their tumour type and disease stage.
-
KRAS mutation status: Kirsten rat sarcoma virus homolog (KRAS) glycine-to-cysteine (G12C) mutation in tumour tissue or blood based on previously performed local testing using a validated test.
-
Provision of archival tumour tissue, if available, to confirm retrospectively KRAS G12C mutation status and for biomarker assessment.
-
At least one target lesion that can be measured per Response Evaluation Criteria In Solid Tumours (RECIST) version 1.1 (radiated lesions do not qualify as target lesions). In patients who only have one target lesion, and a biopsy of the lesion is required, the baseline imaging must be performed before the biopsy or at the earliest two weeks after the biopsy.
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
-
Adequate organ function as follows:
- Absolute neutrophil count (ANC) ≥1.5 x 10^9/L (equivalent values: ≥ 1.5 x 10³/μL or ≥ 1500/mm³); hemoglobin ≥9.0 g/dL (equivalent values: ≥ 90 g/L or ≥ 5.6 mmol/L); platelets ≥100 x 10^9/L (equivalent values: ≥ 100 x 10³/μL or ≥ 100 x 10³/mm³) without the use of haematopoietic growth factors.
- Total bilirubin ≤1.5 times the upper limit of normal (ULN), or ≤4 x ULN for patients who are known to have Gilbert's syndrome.
- Creatinine ≤1.5 x ULN. If creatinine is >1.5 x ULN, patient is eligible if concurrent creatinine clearance ≥50 mL/min (equivalent value: 0.84mL/s) (measured or calculated by Cockcroft-Gault formula).
- Aspartate transaminase (AST) and alanine transaminase (ALT) ≤3 x ULN, for patients with liver metastases ≤5 x ULN.
-
Age ≥18 years of age, or over the legal age of consent as required by local legislation.
Further inclusion criteria apply.
Exclusion Criteria:
- Previous anticancer chemotherapy within 3 weeks of the first administration of trial drug. Previous anticancer hormonal treatment or anticancer immunotherapy within 2 weeks of the first administration of trial drug.
- Previous treatment with Rat Sarcoma (RAS), Mitogen-activated protein kinase (MAPK) or Son of sevenless 1 (SOS1) targeting agents (only for monotherapy Parts A, B, and C).
- Radiotherapy within 2 weeks prior to start of treatment, provided recovery from related toxicity.
- Major surgery (major according to the investigator's assessment) performed within 4 weeks prior to start of treatment or planned during the projected course of the trial, e.g. hip replacement.
- Previous treatment with any investigational agent(s) or targeted treatment within 28 days prior to start of treatment or 5 half-lives, whichever is shorter.
- Known history of hypersensitivity to any of the excipients of BI 1823911 tablets, or any contraindication to Midazolam (for Monotherapy Part B only).
- History or presence of cardiovascular abnormalities such as congestive heart failure New York Heart Association (NYHA) classification of ≥3, unstable angina or poorly controlled arrhythmia which are considered clinically relevant by the Investigator. Myocardial infarction within 6 months prior to start of treatment. Uncontrolled hypertension defined as: Blood pressure (BP) measured in a rested and relaxed condition, where systolic BP >=140 mmHg, or diastolic BP >= 90 mmHg, with or without medication.
- Left ventricular ejection fraction (LVEF) <50%. Further exclusion criteria apply.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição sequencial
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Monotherapy Arm
Each arm consists of three parts (dose escalation (A), dose confirmation (B), and dose expansion (C). |
BI 1823911 Midazolam - only administered in Part B (dose confirmation) of the Monotherapy Arm |
|
Experimental: Combination Therapy Arm
Will be started after confirmation of safety in the Monotherapy Arm. Each arm consists of three parts (dose escalation (A), dose confirmation (B), and dose expansion (C). |
BI 1823911 BI 1701963 |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Dose escalation (Part A) - Monotherapy and combination therapy: Number of patients experiencing Dose limiting toxicities (DLTs) during the Maximum tolerated dose (MTD) evaluation period for BI 1823911 in monotherapy and in each combination
Prazo: up to 28 days
|
DLTs are graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. |
up to 28 days
|
|
Dose confirmation (Part B) and expansion (Part C) - Monotherapy and combination therapy: Objective response (OR) defined as best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR)
Prazo: up to 39 months
|
BOR is determined according to Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1. BOR will consider all tumour assessments from first treatment administration until the earliest of disease progression, death, or last evaluable tumour assessment before start of subsequent anti-cancer therapy, loss to follow-up, or withdrawal of consent. |
up to 39 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Escalonamento de dose (Parte A) - Monoterapia e terapia combinada: Número de pacientes com DLTs durante todos os ciclos de tratamento para BI 1823911 em monoterapia e em cada combinação
Prazo: até 39 meses
|
até 39 meses
|
|
|
Todas as partes do estudo: Número de pacientes com eventos adversos durante o período de tratamento
Prazo: até 39 meses
|
até 39 meses
|
|
|
Todas as partes do estudo, BI 1823911: concentração máxima (Cmax)
Prazo: até 24 horas
|
até 24 horas
|
|
|
Todas as partes do estudo, BI 1823911: Concentração em estado estacionário (Css)
Prazo: até 24 horas
|
até 24 horas
|
|
|
Todas as partes do estudo, BI 1823911: Área sob a curva de concentração plasmática-tempo do tempo zero ao tempo t (AUCτ)
Prazo: até 24 horas
|
até 24 horas
|
|
|
Todas as partes do estudo, BI 1823911: Área sob a curva de concentração plasmática-tempo no estado estacionário (AUCss)
Prazo: até 24 horas
|
até 24 horas
|
|
|
Todas as partes do estudo, BI 1701963: concentração máxima (Cmax)
Prazo: até 24 horas
|
até 24 horas
|
|
|
Todas as partes do estudo, BI 1701963: Concentração em estado estacionário (Css)
Prazo: até 24 horas
|
até 24 horas
|
|
|
Todas as partes do estudo, BI 1701963: Área sob a curva de concentração plasmática-tempo do tempo zero ao tempo t (AUCτ)
Prazo: até 24 horas
|
até 24 horas
|
|
|
Todas as partes do estudo, BI 1701963: Área sob a curva de concentração plasmática-tempo no estado estacionário (AUCss)
Prazo: até 24 horas
|
até 24 horas
|
|
|
Dose confirmation (Part B) and expansion (Part C) - Monotherapy and combination therapy: Objective response (OR)
Prazo: up to 39 months
|
OR is defined as best overall response (BOR) of complete response (CR) or partial response (PR), both regardless of confirmation. BOR is determined according to RECIST version 1.1. BOR will consider all tumour assessments from first treatment administration until the earliest of disease progression, death, or last evaluable tumour assessment before start of subsequent anti-cancer therapy, loss to follow-up, or withdrawal of consent. |
up to 39 months
|
|
Dose confirmation (Part B) and expansion (Part C) - Monotherapy and combination therapy: Duration of OR
Prazo: up to 39 months
|
Duration of OR is defined as the time from first documented CR or PR until disease progression or death (whichever occurs first) among patients with OR. |
up to 39 months
|
|
Dose confirmation (Part B) and expansion (Part C) - Monotherapy and combination therapy: Tumour shrinkage (in millimetres)
Prazo: up to 39 months
|
Tumour shrinkage is defined as the difference between the minimum post-baseline sum of diameters of target lesions (longest for non-nodal lesions, short axis for nodal lesions) and the baseline sum of longest diameters of the same set of target lesions. |
up to 39 months
|
|
Dose confirmation (Part B) and expansion (Part C) - Monotherapy and combination therapy: Progression-free survival (PFS) rate
Prazo: at month 6
|
PFS is defined as the time from first treatment administration until tumour progression according to RECIST version 1.1 or death from any cause, whichever occurs earlier. |
at month 6
|
Colaboradores e Investigadores
Patrocinador
Publicações e links úteis
Links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 1472-0001
- 2021-000460-29 (Número EudraCT)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization).
For more details refer to: https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .